Marczyk, Michal
Qing, Tao
O’Meara, Tess
Yagahoobi, Vesal
Pelekanou, Vasiliki
Bai, Yalai
Reisenbichler, Emily http://orcid.org/0000-0002-1570-6538
Cole, Kimberly S.
Li, Xiaotong
Gunasekharan, Vignesh
Ibrahim, Eiman
Fanucci, Kristina http://orcid.org/0000-0003-3400-7211
Wei, Wei
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Blenman, Kim R. M. http://orcid.org/0000-0001-6070-0728
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219647, R01CA219647)
Susan G. Komen (Leadership Award, Leadership Award)
Howard Hughes Medical Institute (Medical Research Fellow Award, Medical Research Fellow Award)
Breast Cancer Research Foundation (Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 4 September 2021
Accepted: 20 June 2022
First Online: 22 July 2022
Competing interests
: M.M., T.Q., T.O., V.Y., Y.B., E.R, X.L., V.G., and E.I. declare no Competing Financial or Non-Financial Interests. The following authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: K.S.C. is now an employee of Sema4 Genomics. L.P. has received consulting fees and honoraria from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. D.L.R. reports grants and personal fees from Amgen, grants and personal fees from Astra Zeneca, personal fees from Cell Signaling Technology, grants and personal fees from Cepheid, personal fees from Danaher, personal fees from Fluidigm, personal fees from GSK, grants and personal fees from Konica—Minolta, grants and personal fees from Lilly, personal fees from Merck, personal fees from Monopteros, personal fees from NanoString, grants and personal fees from NextCure, personal fees from Odonate, personal fees from Paige.AI, personal fees from Regeneron, personal fees from Roche, personal fees from Sanofi, personal fees from Ventana, and personal fees from Verily outside the submitted work. V.P. is now an employee of Sanofi. K.R.M.B. serves on the Scientific Advisory Board of CDI Labs as a non-financial interest.